UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 


 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): December 28, 2017

 


 

SteadyMed Ltd.

(Exact name of registrant as specified in its charter)

 

Israel

 

001-36889

 

Not applicable

(State or other jurisdiction of
incorporation)

 

(Commission File Number)

 

(IRS Employer
Identification No.)

 

5 Oppenheimer Street
Rehovot 7670105, Israel

(Address of principal executive offices, including zip code)

 

925-272-4999

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

 

 

 



 

Item 5.07. Submission of Matters to a Vote of Security Holders.

 

The following is a summary of the proposals and the voting results from the Company’s 2017 Annual Meeting of Shareholders on December 28, 2017 (the “Annual Meeting”). A more complete description of each matter is described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on November 20, 2017 (the “Proxy Statement”).

 

Proposal 1 — Election of Directors. The Company’s shareholders elected Jonathan Rigby and Ron Ginor to serve as Class III directors of the Company, each for a term of three years, to hold office until the Company’s 2020 Annual General Meeting of Shareholders. The voting results are as follows:

 

Name

 

For

 

Against

 

Abstain

 

Broker Non-Vote

Jonathan Rigby

 

21,518,007

 

154,607

 

3,135

 

2,406,036

Ron Ginor

 

21,513,007

 

159,607

 

3,135

 

2,406,036

 

Proposal 2 — Appointment of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, as the Company’s Independent Auditor for the year ending December 31, 2017. The Company’s shareholders approved the appointment of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, as the Company’s independent auditor for the year ending December 31, 2017. The voting results are as follows:

 

For

 

Against

 

Abstain

23,932,224

 

112,576

 

36,985

 

Proposal 3 — Approval of the Grant of Stock Options to Non-Employee Directors of the Board of Directors of the Company. The Company’s shareholders approved the grant of stock options to the non-employee directors of the Board of Directors of the Company. The voting results are as follows, including the disclosure of personal interest:

 

For

 

Against

 

Abstain

 

Broker Non-Vote

16,496,146

 

5,171,013

 

2,961

 

2,411,665

 

Indication of Personal Interest

Yes

 

No

8,432,260

 

13,071,108

 

Proposal 4 — Approval of the Grant of Stock Options and Restricted Stock Units to Mr. Jonathan Rigby, President and Chief Executive Officer of the Company. The Company’s shareholders approved the grant of stock options and restricted stock units to Mr. Jonathan Rigby, President and Chief Executive Officer of the Company. The voting results are as follows, including the disclosure of personal interest:

 

For

 

Against

 

Abstain

 

Broker Non-Vote

16,494,103

 

5,171,926

 

3,941

 

2,411,815

 

Indication of Personal Interest

Yes

 

No

2,584,165

 

18,960,015

 

2



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

STEADYMED LTD.

 

 

 

 

By:

/s/ David W. Nassif

Date: January 4, 2018

 

David W. Nassif

 

 

Chief Financial Officer

 

3


STEADYMED LTD. (NASDAQ:STDY)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more STEADYMED LTD. Charts.
STEADYMED LTD. (NASDAQ:STDY)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more STEADYMED LTD. Charts.